181 related articles for article (PubMed ID: 38829047)
1. Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review.
Tambe S; Nag S; Pandya SR; Kumar R; Balakrishnan K; Kumar R; Kumar S; Amin P; Gupta PK
ACS Infect Dis; 2024 Jun; 10(6):1871-1889. PubMed ID: 38829047
[TBL] [Abstract][Full Text] [Related]
2. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
4. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
[TBL] [Abstract][Full Text] [Related]
5. Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.
Wagner V; Minguez-Menendez A; Pena J; Fernández-Prada C
Curr Pharm Des; 2019; 25(14):1582-1592. PubMed ID: 31223081
[TBL] [Abstract][Full Text] [Related]
6. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
7. Recent advances and new strategies on leishmaniasis treatment.
Roatt BM; de Oliveira Cardoso JM; De Brito RCF; Coura-Vital W; de Oliveira Aguiar-Soares RD; Reis AB
Appl Microbiol Biotechnol; 2020 Nov; 104(21):8965-8977. PubMed ID: 32875362
[TBL] [Abstract][Full Text] [Related]
8. Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives.
Téllez J; Echeverry MC; Romero I; Guatibonza A; Santos Ramos G; Borges De Oliveira AC; Frézard F; Demicheli C
J Liposome Res; 2021 Jun; 31(2):169-176. PubMed ID: 32228210
[TBL] [Abstract][Full Text] [Related]
9. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.
de Almeida L; Terumi Fujimura A; Del Cistia ML; Fonseca-Santos B; Braga Imamura K; Michels PAM; Chorilli M; Graminha MAS
J Biomed Nanotechnol; 2017 Feb; 13(2):117-33. PubMed ID: 29376626
[TBL] [Abstract][Full Text] [Related]
11. Anti-leishmanial Nanotherapeutics: A Current Perspective.
Shah A; Gupta SS
Curr Drug Metab; 2019; 20(6):473-482. PubMed ID: 30360732
[TBL] [Abstract][Full Text] [Related]
12. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
13. An update on small molecule strategies targeting leishmaniasis.
Kapil S; Singh PK; Silakari O
Eur J Med Chem; 2018 Sep; 157():339-367. PubMed ID: 30099256
[TBL] [Abstract][Full Text] [Related]
14. Marine Algae as Source of Novel Antileishmanial Drugs: A Review.
Tchokouaha Yamthe LR; Appiah-Opong R; Tsouh Fokou PV; Tsabang N; Fekam Boyom F; Nyarko AK; Wilson MD
Mar Drugs; 2017 Oct; 15(11):. PubMed ID: 29109372
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis.
Vaghela R; Kulkarni PK; Osmani RAM; Bhosale RR; Naga Sravan Kumar Varma V
Curr Drug Targets; 2017; 18(14):1598-1621. PubMed ID: 27033193
[TBL] [Abstract][Full Text] [Related]
17. Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis.
Rub A; Shaker K; Kashif M; Arish M; Dukhyil AAB; Alshehri BM; Alaidarous MA; Banawas S; Amir K
Protein Pept Lett; 2019; 26(5):371-376. PubMed ID: 30827222
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Ponte-Sucre A; Gamarro F; Dujardin JC; Barrett MP; López-Vélez R; García-Hernández R; Pountain AW; Mwenechanya R; Papadopoulou B
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006052. PubMed ID: 29240765
[TBL] [Abstract][Full Text] [Related]
19. Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis - A review.
Prasanna P; Kumar P; Kumar S; Rajana VK; Kant V; Prasad SR; Mohan U; Ravichandiran V; Mandal D
Biomed Pharmacother; 2021 Sep; 141():111920. PubMed ID: 34328115
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured delivery systems with improved leishmanicidal activity: a critical review.
Bruni N; Stella B; Giraudo L; Della Pepa C; Gastaldi D; Dosio F
Int J Nanomedicine; 2017; 12():5289-5311. PubMed ID: 28794624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]